BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders elected three Class I directors to serve until the 2029 annual meeting. Director Randal W. Scott resigned at the end of his term, and the company stated his resignation was not due to any disagreement.
Stockholders approved, on an advisory basis, the compensation of named executive officers and chose an annual frequency for future say‑on‑pay votes. They also ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.
Shareholders approved an amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 2,000,000 shares.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares entitled to vote: 195,806,242 shares
Shares present or by proxy: 175,706,357 shares
Plan share increase: 2,000,000 shares
+3 more
6 metrics
Shares entitled to vote
195,806,242 shares
Common stock entitled to vote at the 2026 annual meeting
Shares present or by proxy
175,706,357 shares
Common stock present or represented at the 2026 annual meeting
Plan share increase
2,000,000 shares
Additional common stock reserved under the 2021 Stock Option and Incentive Plan
Votes for James C. Momtazee
156,790,852 votes
Election as Class I director
Say-on-pay support
152,949,577 votes for
Non-binding advisory approval of named executive officer compensation
Auditor ratification votes for
175,420,234 votes
Ratification of Deloitte & Touche LLP for year ending December 31, 2026
Key Terms
broker non-votes, non-binding advisory vote, independent registered public accounting firm, Stock Option and Incentive Plan, +1 more
5 terms
broker non-votes financial
"There were 14,599,487 broker non-votes regarding this proposal."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory vote financial
"The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers."
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
independent registered public accounting firm financial
"ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Stock Option and Incentive Plan financial
"approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board changes did BridgeBio Pharma (BBIO) announce from the 2026 annual meeting?
BridgeBio reported that Dr. Randal W. Scott resigned from the board upon completion of his term as a Class I director on June 22, 2026. The company stated his resignation was not due to any disagreement over operations, policies, or practices.
Which directors were elected at BridgeBio Pharma’s 2026 annual meeting?
Shareholders elected three Class I directors: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve until the 2029 annual meeting or until successors are elected and qualified. Each received a majority of votes cast at the meeting.
What frequency did BridgeBio Pharma investors choose for future say-on-pay votes?
Investors supported holding non-binding advisory votes on executive compensation every one year, with 154,371,970 votes for a one-year frequency. Smaller totals were cast for two-year and three-year options, and the company plans to follow this annual preference going forward.
Did BridgeBio Pharma (BBIO) change its stock incentive plan at the 2026 meeting?
Yes. Shareholders approved an amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 2,000,000 shares. The amended plan is included as Exhibit 10.1 to the report.
Who is BridgeBio Pharma’s independent auditor for the year ending December 31, 2026?
Shareholders ratified Deloitte & Touche LLP as BridgeBio’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 175,420,234 votes for, 203,310 against, and 82,813 abstentions, and no broker non-votes on this proposal.